Taysha Gene Therapies, Inc. (TSHA): Entry into a Material Definitive Agreement
Taysha Gene Therapies, Inc. (TSHA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d121397dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Taysha Gene Therapies, Inc. Common Stock Pre-Funded Warrants Underwriting Agreement June 24, 2026 Jefferies LLC Goldman Sachs & Co. LLC As representatives of the several Underwriters named in Schedule I hereto c/o Jefferies LLC
How this was made
The 30-second read
Why it matters
The disclosed issuance structure (firm shares, optional shares, and pre-funded warrants) signals a capital raise; traders typically reprice for dilution risk and potential changes in financing runway.
Market read
New equity/warrant issuance terms are disclosed, creating an actionable dilution/overhang narrative for TSHA into the next trading session.
What to watch
Key missing details (offering price, expected closing date, use of proceeds, and whether warrants are dilutive beyond the exercise price) could materially change the trade setup.
Background
The 8-K reports entry into a material definitive agreement for an underwriting of common stock and pre-funded warrants under an existing shelf registration.
Ticker impact
TSHA entered a material definitive underwriting agreement to issue 32.5M common shares plus pre-funded warrants, with up to 5M optional shares.
Likely near-term negative-to-neutral bias from dilution/overhang; magnitude depends on offering size vs current float and any disclosed pricing terms (not included here).
This is a primary 8-K disclosure of an underwriting agreement and share/warrant quantities, but the excerpt omits key economics (offering price, warrant terms beyond exercise price, net proceeds).
Market effects
Gene therapy/small-cap biotech financing risk may remain elevated; could modestly affect sentiment toward similarly capital-constrained issuers.
Primarily US small-cap biotech sentiment; limited direct regional spillover beyond the US-listed peer set.
Low global relevance; mostly affects US biotech capital markets and risk appetite for pre-revenue/early-stage names.
Counterpoint
If the offering price is at a premium and proceeds fund near-term clinical/regulatory milestones, the dilution overhang may be quickly absorbed.
Key entities
- issuerTaysha Gene Therapies, Inc.
Subject of the 8-K; entered the underwriting agreement for common stock and pre-funded warrants.
- underwriterJefferies LLC
One of the representatives/underwriters in the underwriting agreement.
- underwriterGoldman Sachs & Co. LLC
One of the representatives/underwriters in the underwriting agreement.
